Umbilical Cord Mesenchymal Stem Cells Injection for Ocular Corneal Burn
NCT ID: NCT03237442
Last Updated: 2017-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
100 participants
INTERVENTIONAL
2018-01-01
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
the Treatment of Human Bone Marrow Mesenchymal Stem Cells in Ocular Corneal Burn
NCT02325843
Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction
NCT01237600
Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells
NCT04224207
Stem Cells Therapy for Corneal Blindness
NCT02948023
Cord Blood Serum in the Treatment of Ocular Surface Diseases
NCT01234623
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1
human umbilical cord mesenchymal stem cells
human UC-MSCs: 0.2ml(about 2\*10\^6 cells) subconjunctival injection
group 2
placebo
Saline injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
human umbilical cord mesenchymal stem cells
human UC-MSCs: 0.2ml(about 2\*10\^6 cells) subconjunctival injection
placebo
Saline injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* the subjects are willing to accept this research, and promise to coordinate with the researchers during the follow up period;
* the subjects should abide by the laws and rules of the study.
Exclusion Criteria
* have corneal perforation or have the corneal perforation tendency;
* have been accepted surgery on eyeball after trauma;
* IOP\>=25 mmHg even after antiglaucoma;
* have the history of other corneal disease or surgery;
* have the history of radiotherapy or surgery in the eyeball;
* associated with corneal ulcer or endoophthalmitis;
* uncontrolled hypertension(\>=150/95 mmHg);
* abnormal liver and renal function;
* the pregnant women.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou Saliai Stem Cell Science and Technology Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yanyan Ma
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SSCST-MSC-OCB-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.